Refrigeration (2-8C / 36-46F): The Standard Protocol This is the sweet spot
Storage Storage recommendations should always follow the manufacturer's documentation
Tirzepatide's dual receptor mechanism How tirzepatide works: Dual GIP/GLP-1 receptor agonist Single molecule, two pathways GIP (glucose-dependent insulinotropic polypeptide) + GLP-1 Weekly subcutaneous injection FDA approved for diabetes and obesity GIP pathway effects: Enhances insulin secretion Improves insulin sensitivity Promotes fat metabolism Reduces inflammation Works synergistically with GLP-1 GLP-1 pathway effects: Suppresses appetite (central brain effects) Slows gastric emptying (moderate) Increases satiety Reduces glucagon Improves glucose control Combined tirzepatide results: 15-22% average body weight loss (monotherapy) Superior to semaglutide (GLP-1 alone) Well-tolerated in trials Approved and available See our tirzepatide dosing guide , semaglutide vs tirzepatide , and peptides for weight loss at SeekPeptides
The key predictors of successful weight maintenance after stopping include the amount of muscle mass preserved during weight loss, dietary habits established during treatment, physical activity level, and psychological readiness for increased appetite
Because the geometric mean cost of CPT code 78433 is still within the range for APC 1522, the proposed APC assignment for CPT code 78433 for CY 2026, we are finalizing the proposed APC assignment of CPT code 78433 without modification
